Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

Clicks: 391
ID: 113195
1994
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Previously, recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fabs were generated by antigen selection from random combinatorial libraries displayed at the tip of filamentous phage. Two such Fabs, which exhibited high binding affinity for RSV F glycoprotein (a major protective …
Reference Key
je1994proceedingsrecombinant Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Crowe JE;Murphy BR;Chanock RM;Williamson RA;Barbas CF;Burton DR;;
Journal Proceedings of the National Academy of Sciences of the United States of America
Year 1994
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8108420
Keywords
immunization Administration National Center for Biotechnology Information NCBI NLM MEDLINE Mice animals humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female Recurrence Antibodies Monoclonal / therapeutic use* Inbred BALB C immunotherapy b r murphy passive* respiratory syncytial virus infections / therapy* viral / administration & dosage pmid:8108420 pmc43163 doi:10.1073/pnas.91.4.1386 j e crowe d r burton intranasal monoclonal / administration & dosage viral / therapeutic use* immunoglobulin fab fragments / administration & dosage immunoglobulin fab fragments / therapeutic use* lung diseases / therapy recombinant proteins / administration & dosage recombinant proteins / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.